You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Item added

What is Anoro Ellipta?

Indication

Anoro Ellipta is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD. 1

Dosing

The recommended and maximum dose of Anoro Ellipta (UMEC/VI 55/22 mcg) is one inhalation once a day. If a dose is missed the next dose should be taken at the usual time the next day. 1

MEET HANNAH*

AGE: 56
mMRC🛈 : 2
CAT SCORE 🛈: 10
FEV1 predicted: 65%
GOLD PATIENT GROUP: B
EXACERBATION HISTORY: None within the last 12 months
SYMPTOMS: Breathless on exertion, walks slower than others her age
HANNAH IS STILL BREATHLESS DESPITE AS-NEEDED SABA**

* Fictional patient
** Short-acting beta2 agonist

References:

  1. Anoro SmPC
  2. Stenton et al. Occupational Medicine; 2008: 58:226–227.
  3. Müllerová, H., et al., PLOS ONE, 2014. 9(1). p. e85540.
  4. Oba Y et al. Thorax 2016; 71:15-25.
  5. Maleki-Yazdi M et al. Adv Ther 2016; 33:2188-2199.
  6. GSK DATA on file: RF/UCV/0112/15(1).
  7. Decramer M et al. Lancet Respir Med 2014; 2:472-486.
  8. Feldman G.J. et al. Adv Ther 2017; 34:doi 10.1007/s12325-017-0626-4.
  9. Riley J et al. Int J Chron Obstruct Pulmon Dis 2016; 11:1873-1880.
  10. Svedsater H et al. BMC pulm Med 2013; 13:72-86.
  11. Van der Palen J et al. NPJ Primare Respir Med 2016; 26:16079.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.

Anoro and Ellipta are registered trademarks of the GlaxoSmithKline group of companies